Document is current
Any future updates will be listed below
-
Authors
Coutzac, Clélia https://orcid.org/0000-0002-8347-6957
Jouniaux, Jean-Mehdi
Paci, Angelo https://orcid.org/0000-0002-4849-0825
Schmidt, Julien
Mallardo, Domenico https://orcid.org/0000-0002-1081-5313
Seck, Atmane
Asvatourian, Vahe
Cassard, Lydie https://orcid.org/0000-0001-8373-041X
Saulnier, Patrick
Lacroix, Ludovic
Woerther, Paul-Louis
Vozy, Aurore
Naigeon, Marie
Nebot-Bral, Laetitia
Desbois, Mélanie https://orcid.org/0000-0001-5503-8821
Simeone, Ester
Mateus, Christine
Boselli, Lisa
Grivel, Jonathan
Soularue, Emilie
Lepage, Patricia https://orcid.org/0000-0002-9501-6771
Carbonnel, Franck
Ascierto, Paolo Antonio https://orcid.org/0000-0002-8322-475X
Robert, Caroline https://orcid.org/0000-0002-9493-0238
Chaput, Nathalie https://orcid.org/0000-0003-3968-8669
- License Information
-
More Information
Article History
Received: 4 April 2019
Accepted: 8 April 2020
First Online: 1 May 2020
Competing interests
: N.C. reports research grants from Cytune Pharma, GSK, Sanofi, has participated in advisory boards for AstraZeneca and has been a speaker for Sanofi and AstraZeneca. C.R. has participated in advisory boards for Roche, GSK, Merck, Novartis, Amgen, BMS and Novartis. Franck Carbonnel received boards or lecture fees from enterome, Amgen, Astra, MSD, BMS, Janssen, Pfizer, Abbvie, Mayoly Spindler, Takeda, Pileje, Roche. E. Soularue has participated in advisory board for Novartis. L.L. has participated in advisory boards for Roche, Astrazeneca, BMS, Genomic Health, Illumina, Qiagen, Novartis Thermofisher and has been a speaker for Amgen, AstraZeneca, Dyn, Vela diagnostics, Luye Pharma, and Roche. P.A.A. has/had a consultant/advisory role for Bristol Myers-Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Amgen, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera. He also received Research funds from Bristol Myers-Squibb, Roche-Genentech, Array. The other authors have no conflicts of interest to declare.
